Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity encouraged by B&M's turnaround, stays at 'buy'

(Sharecast News) - Canaccord Genuity has reiterated its 'buy' rating for B&M European Value Retail, saying it was encouraging by this week's annual results which showed the discount retailer's turnaround plan was "gaining traction". "FY26 was a challenging year for B&M with flat UK LFLs, and margin pressure from price investment and cost inflation, resulting in a sharp decline in profitability despite continued space-led topline growth," Canaccord Genuity said in a research note on Friday.

While group revenues were up 3.6% at £5.78bn over the year to 28 March, annual pre-tax profits were down 38% at £284m, partly due to increases to the minimum wage, higher employer National Insurance contributions and the recycling levy alongside growth in the retail estate.

However, the broker pointed out that the business finished the year "on a firmer footing, supported by the early benefits from the 'Back to B&M Basics' strategy".

"The execution of the Back to B&M Basics plan is on track with strategic progress being made across pricing, promotions, ranging and availability. The group has sharpened price competitiveness, simplified ranges through SKU reductions and improved on-shelf availability (rising from 86% to 93%), while clearing legacy inventory and refocusing the offer," it said.

The stock currently trades at a price-to-earnings ratio of 9.1 based on 2027 calendar year estimates, which Canaccord Genuity said "offers good value", given its long-term average PER multiple is around 15x.

The broker kept a 230p target price for the stock, which was up 1.4% at 211.16p by 1451 BST.

Share this article

Related Sharecast Articles

Thalia Therapeutics enters new phase of development
(Sharecast News) - Thalia Therapeutics said on Friday that it was entering a new phase of development ahead of its annual general meeting, with the proposed acquisition of Sanmirna Therapeutics and an oversubscribed £2.75m fundraising expected to accelerate its transition into a clinical-stage RNA therapeutics company.
Metir inks water system deal with Portsmouth Aviation
(Sharecast News) - Metir announced Friday that it has signed a memorandum of understanding with Portsmouth Aviation to evaluate integrated water treatment and monitoring systems combining Portsmouth's PaquaVida purification platform with Metir's Modern Water Microtox biological monitoring technology.
System1 reiterates rejection of Brave Bison's revised offer
(Sharecast News) - System1 reiterated its unanimous rejection of Brave Bison's revised cash-and-share proposal on Friday, saying feedback from major shareholders supported the board's view that the offer materially undervalued the company.
ConocoPhillips to buy 42% stake in BP Iraq oil fields
(Sharecast News) - BP said on Friday that it has agreed terms for ConocoPhillips to buy a 42% interest in BP Energy Company of Kirkuk (BP ECKL).

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.